Superior Performance. Reliable Results.

Find It detects common, clinically actionable genomic alterations in solid tumor samples, including single-base substitutions (SNVs), small deletions, and insertions (up to 24bp). It evaluates the mutation status of tumor DNA at 146 hotspots and 23 exons in 30 known cancer-associated genes simultaneously.

Find It detects indications for non-small cell lung cancer, melanoma, colorectal cancer, GIST, basal cell, breast cancer, endometrial, and other solid tumor cancers.

Breast
GeneTherapeutic OptionsPosition
AKT1 E17
ERBB2 G309, S310, L755, C805, Exon20
ESR1 K303, S463, V534, P535, L536, Y537, D538
PIK3CA R88, E542, E545, Q546, D549, M1043, N1044, A1046, H1047, G1049
Colorectal
GeneTherapeutic OptionsPosition
BRAF Q201, G466, F468, G469, Y472, D594, G596, L597, V600, K601
KRAS G12, G13, A59, Q61, K117, A146
NRAS G12, G13, A59, Q61, K117, A146
PIK3CA R88, E542, E545, Q546, D549, M1043, N1044, A1046, H1047, G1049
Endometrial
GeneTherapeutic OptionsPosition
CTNNB1 D32, S33, G34, S37, T41, S45
PIK3CA R88, E542, E545, Q546, D549, M1043, N1044, A1046, H1047, G1049
POLE Exon9, Exon10, Exon11, Exon12, Exon13, Exon14
Melanoma
GeneTherapeutic OptionsPosition
BRAF Q201, G466, F468, G469, Y472, D594, G596, L597, V600, K601
KIT Exon9, Exon11, Exon13, T670, D816, D820, N822, Y823, A829
NRAS G12, G13, A59, Q61, K117, A146
GIST
GeneTherapeutic OptionsPosition
BRAF Q201, G466, F468, G469, Y472, D594, G596, L597, V600, K601
PDGFRA N659, R560-E571, D842, L839-Y849
KIT Exon9, Exon11, Exon13, T670, D816, D820, N822, Y823, A829
Glioma
GeneTherapeutic OptionsPosition
BRAF Q201, G466, F468, G469, Y472, D594, G596, L597, V600, K601
IDH1 R132
IDH2 R140, R172
NSCLC
GeneTherapeutic OptionsPosition
BRAF Q201, G466, F468, G469, Y472, D594, G596, L597, V600, K601
EGFR S492, Exon18, Exon19, Exon20, Exon21
ERBB2 G309, S310, L755, C805, Exon20
KRAS G12, G13, A59, Q61, K117, A146
MET Y1253, Exon13, Exon 14 (-50 to +25), Exon18
Sarcoma
GeneTherapeutic OptionsPosition
GNAS R201
IDH1 R132
IDH2 R140, R172
GenePosition
AKT1E17
ALKT1151, L1152, C1156, F1174, L1196, L1198, G1202, D1203, S1206, G1269, R1275
ARL702H, S741, W742, V716, H875, F877, T878
BRAFQ201, G466, F468, G469, Y472, D594, G596, L597, V600, K601
CTNNB1D32, S33, G34, S37, T41, S45
DDR2L239, I638, S768
EGFRS492, Exon18, Exon19, Exon20, Exon21
ERBB2G309, S310, L755, C805, Exon20
ESR1K303, S463, V534, P535, L536, Y537, D538
GNA11Q209
GNAQQ209
GNASR201
HRASG12, G13, Q61
IDH1R132
IDH2R140, R172
KITExon9, Exon11, Exon13, T670, D816, D820, N822, Y823, A829
KRASG12, G13, A59, Q61, K117, A146
MAP2K1(MEK1)Q56, K57, K59, D67, C121, P124, P387
MAP2K2(MEK2)F57, Q60, K61, L119
METY1253, Exon13, Exon 14 (-50 to +25), Exon18
NRASG12, G13, A59, Q61, K117, A146
PDGFRAN659, R560-E571, D842, L839-Y849
PIK3CAR88, E542, E545, Q546, D549, M1043, N1044, A1046, H1047, G1049
POLEExon9, Exon10, Exon11, Exon12, Exon13, Exon14
PTCH1W844, G1093
PTENR130
RETC634, V804, M918
ROS1L2026, G2032
SMOD473, S533, W535
TP53Exon4, Exon5, Exon6, Exon7, Exon8, Exon9
Genes30
Hotspots146
Exons23
Turnaround Time3-5 days
Mutation typesSNVs, deletions and insertions(up to 24bp)
Sensitivity100%
Specificity100%
Assay CutoffBelow 1% VAF
Average Coverage10,000x
Assay Reproducibility100%
Sample TypeFFPE blocks, scrolls, cores & unstained slides
Sample RequirementFFPE blocks or unstained slides (5µm sections) with a minimum of 10% tumor cellularity. Scrolls, Cores or DNA must be submitted with representative H&E

Benefits

Actionable Results

Targets FDA approved therapies and current clinical trials.

Rapid Turnaround Time

Make clinical decisions faster, with accurate reporting in as little as three days.

Comprehensive Reports

Review detailed interpretations, current treatment options, and available clinical trials.

Cost-Effective

Reduce the financial burden on healthcare providers and patients with an affordable, reimbursable test*.

Conserve Biopsy Tissue

Find It’s single sample panel allows for simultaneous hotspot testing, reducing the amount of biopsy tissue required.

Accreditation

All Canexia Health assays were developed under full accreditation of the CAP and CLIA.

View Other Solutions

Follow It®

A minimally invasive option for biopsy, Follow It can also be used to monitor cancer progression or investigate treatment resistance.

Learn About Follow It

Fusions

Rapid, cost-effective, and clinically actionable, Fusions allows you the flexibility to isolate and interrogate relevant fusions.

Learn About Fusions

Canexia Informatics Platform

Each comprehensive report includes detailed results as well as therapeutic recommendations and expertly curated clinical trials. Our insights can help you make more informed treatment decisions.

Learn About Our Reports

Your Labs, Our Technology

From mutation identification to auto-generated clinical reports, Canexia Health’s proprietary platform allows you to perform mutation assay for cancer patients, right from your laboratory.

Learn More

Make Faster Treatment Decisions

Our clinically-validated and cost-effective assays, informatics, and support offer a complete end-to-end solution, from mutation identification to auto-generated clinical reports.

Get Started Today